Company research
Anbio Biotechnology
CIK 1982708Updated Oct 6, 2026
SecurityNNNN · NASDAQ · equity
NNNN price & chart
Loading TradingView…
NASDAQ:NNNN on TradingView ↗About the company
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. By offering a versatile range of products, we ensure that healthcare providers and patients alike can access reliable and efficient diagnostic tools regardless of the healthcare setting.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 30,242,859Source | 18,921,784Source | 15,811,768Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,766,738Source | 11,760,859Source | 9,687,976Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,655,964Source | 1,064,794Source | 1,884,960Source |
| Assets, CurrentUSD | 30,242,859Source | 18,534,344Source | 15,749,631Source |
| Prepaid Expense and Other Assets, CurrentUSD | 607,072Source | 25,606Source | 403,868Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 87,836Source | 1,730,234Source | 993,060Source |
| Stockholders’ equity: | |||
| Retained Earnings (Accumulated Deficit)USD | 23,577,004Source | 17,173,541Source | 14,800,699Source |
| Stockholders' Equity Attributable to ParentUSD | 30,155,023Source | 17,191,550Source | 14,818,708Source |
| Additional Paid in Capital, Common StockUSD | 6,563,630Source | 3,780Source | 3,780Source |
| Liabilities and EquityUSD | 30,242,859Source | 18,921,784Source | 15,811,768Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 87,836Source | 1,730,234Source | 993,060Source |
| Accounts Payable, CurrentUSD | 0Source | 1,625,255Source | 827,151Source |
| Additional Financial Items | |||
| Short-term InvestmentsUSD | 4,134,493Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | 2,591,170Source | -820,166Source | 1,884,960Source |
| Increase (Decrease) in InventoriesUSD | — | — | -353,872Source |
| Increase (Decrease) in Accounts PayableUSD | -1,625,255Source | 798,104Source | -580,891Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -6,739,075Source | 2,080,387Source | 898,367Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -4,202,496Source | 337,101Source | 1,730,173Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,947,450Source | -344,605Source | -42,835Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 7,766,738Source | 11,760,859Source | 9,687,976Source |
| Additional Financial Items | |||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 493,562Source | 20,469Source | 119,419Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Investment Income, InterestUSD | 142,023Source | 337,511Source | 165,336Source |
| Net Income (Loss) Attributable to ParentUSD | 6,403,463Source | 2,372,842Source | 2,253,709Source |
| Nonoperating Income (Expense)USD | 635,723Source | 377,475Source | 292,780Source |
| Operating ExpensesUSD | 1,775,422Source | 3,890,017Source | 1,399,940Source |
| Proceeds from Issuance of Common StockUSD | 7,230,000Source | — | — |
| Realized Investment Gains (Losses)USD | -68,003Source | 337,101Source | 163,388Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 8,646,844Source | 8,185,146Source | 6,711,990Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 8,646,844Source | 8,185,146Source | 6,711,990Source |
| Cost of Goods and Services Sold | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | 1,574,117Source | 3,435,790Source | 1,265,240Source |
| Operating Income (Loss)USD | 5,767,740Source | 1,995,367Source | 1,960,929Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 6,403,463Source | 2,372,842Source | 2,253,709Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 6,403,463Source | 2,372,842Source | 2,253,709Source |
| Earnings Per Share, BasicUSD per share | 0.15Source | 0.06Source | 0.11Source |
| Earnings Per Share, DilutedUSD per share | 0.15Source | 0.06Source | 0.11Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 43,672,022Source | 42,291,202Source | 21,435,316Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 43,672,022Source | — | — |
| Additional Financial Items | |||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 493,562Source | 20,469Source | 119,419Source |
| Gross ProfitUSD | 7,543,162Source | 5,885,384Source | 3,360,869Source |
| Interest Income, OtherUSD | — | 337,101Source | 163,388Source |
| Investment Income, InterestUSD | 142,023Source | 337,511Source | 165,336Source |
| Nonoperating Income (Expense)USD | 635,723Source | 377,475Source | 292,780Source |
| Operating ExpensesUSD | 1,775,422Source | 3,890,017Source | 1,399,940Source |
| Realized Investment Gains (Losses)USD | -68,003Source | 337,101Source | 163,388Source |
| Research and Development ExpenseUSD | 201,305Source | 454,227Source | 134,700Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 8,646,844Source | 8,185,146Source | 6,711,990Source |
Offerings
Registration 333-297349
Registration 333-284106
- Gross proceeds
- 8000000.0
- Net proceeds
- 7440000.0
- Deal price
- 5.0
- Shares
- 1600000
- Offering price
- $5.00
- Ticker
- NNNN
Filing attachments
anbioex4-1.htm · F-3ASR · 2026-07-09
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of this registration statement on Form F-3 of which this Exhibit 4.1 is a part, Anbio Biotechnology (the “Company”, “we”, “us” or “our”) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company’s Class A Ordinary Shares (the “Class A Ordinary Shares”). Description of Class A Ordinary…
Read attachment ↗anbioex4-2.htm · F-3ASR · 2026-07-09
Exhibit 4.2 Anbio Biotechnology FORM OF SENIOR INDENTURE Dated as of [ ], 2026 [ ] Trustee TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS AND INCORPORATION 1 BY REFERENCE SECTION 1.01. Definitions. 1 SECTION 1.02…
Read attachment ↗anbioex4-3.htm · F-3ASR · 2026-07-09
Exhibit 4.3 Anbio Biotechnology FORM OF SUBORDINATED INDENTURE Dated as of [ ], 2026 [ ] Trustee TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS AND INCORPORATION 1 BY REFERENCE SECTION 1.01. Definitions. 1 SECTION 1.02. …
Read attachment ↗anbioex99-1.htm · 6-K · 2026-04-27
Exhibit 99.1 Anbio Biotechnology Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt am Main, Germany PROXY STATEMENT AND NOTICE OF A MEETING OF THE HOLDERS OF CLASS A ORDINARY SHARES TO BE HELD ON May 15, 2026 AND PROXY STATEMENT AND NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD IMMEDIATELY FOLLOWING THE MEETING OF THE HOLDERS OF THE CLASS A ORDINARY SHARES NOTICE OF A MEETING OF THE HOLDERS OF CLASS A ORDINARY SHARES April 27, 2026 Dear Shareholder: Notice is hereby …
Read attachment ↗anbioex99-2.htm · 6-K · 2026-04-27
Exhibit 99.2 Control Number: Number of Shares: Registered Shareholder: ─────────────────────────────────────────────────────────────────────── Anbio Biotechnology Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt am Main, Germany PROXY Solicited on Behalf of the Board of Directors for the Meeting of Shareholders of Class A Ordinary Shares on May 15, 2026 at 3 p.m., Germany Time (May 15, 2026 at 9 a.m., Eastern Time) The Meeting Materials for the Meeting of shareholders of Class …
Read attachment ↗